Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Mickey Williams

Showing results (31-40 of 86) with videos related to

Pageof 9
Sort By:
Clinical Chemistry|August 23, 2008
Intraplatform reproducibility and technical precision of gene expression profiling in 4 laboratories investigating 160 leukemia samples: the DACH studyAlexander Kohlmann, Elisabeth Haschke-Becher, Barbara Wimmer, et al.
The Journal of Molecular Diagnostics : JMD|July 27, 2016
Certified DNA Reference Materials to Compare HER2 Gene Amplification Measurements Using Next-Generation Sequencing MethodsChih-Jian Lih, Han Si, Biswajit Das, et al.
NPJ Precision Oncology|September 6, 2022
Circulating tumor DNA sequencing provides comprehensive mutation profiling for pediatric central nervous system tumorsErin R Bonner, Robin Harrington, Augustine Eze, et al.
BMC Medicine|November 16, 2013
Criteria for the use of omics-based predictors in clinical trials: explanation and elaborationLisa M McShane, Margaret M Cavenagh, Tracy G Lively, et al.
JCO Precision Oncology|July 12, 2021
Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of HealthP Mickey Williams, Thomas Forbes, Steven P Lund, et al.
Nature|October 18, 2013
Criteria for the use of omics-based predictors in clinical trialsLisa M McShane, Margaret M Cavenagh, Tracy G Lively, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2025
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1KCarolyn K McCourt, Zihan Wei, Kevin Kalinsky, et al.
JCO Precision Oncology|February 20, 2026
Larotrectinib in Patients With Tumors With <i>NTRK</i> Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1ENeal Akhave, Zihe Song, David S Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study GroupTorsten Haferlach, Alexander Kohlmann, Lothar Wieczorek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2025
Concordance between tumor tissue and plasma DNA genotyping in the NCI-MATCH trial (EAY131)Mohamed A Gouda, Filip Janku, Ying Yuan, et al.
Pageof 9

Showing results (31-40 of 86) with videos related to

Sort By:
Pageof 9
Clinical Chemistry|August 23, 2008
Intraplatform reproducibility and technical precision of gene expression profiling in 4 laboratories investigating 160 leukemia samples: the DACH studyAlexander Kohlmann, Elisabeth Haschke-Becher, Barbara Wimmer, et al.
The Journal of Molecular Diagnostics : JMD|July 27, 2016
Certified DNA Reference Materials to Compare HER2 Gene Amplification Measurements Using Next-Generation Sequencing MethodsChih-Jian Lih, Han Si, Biswajit Das, et al.
NPJ Precision Oncology|September 6, 2022
Circulating tumor DNA sequencing provides comprehensive mutation profiling for pediatric central nervous system tumorsErin R Bonner, Robin Harrington, Augustine Eze, et al.
BMC Medicine|November 16, 2013
Criteria for the use of omics-based predictors in clinical trials: explanation and elaborationLisa M McShane, Margaret M Cavenagh, Tracy G Lively, et al.
JCO Precision Oncology|July 12, 2021
Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of HealthP Mickey Williams, Thomas Forbes, Steven P Lund, et al.
Nature|October 18, 2013
Criteria for the use of omics-based predictors in clinical trialsLisa M McShane, Margaret M Cavenagh, Tracy G Lively, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2025
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1KCarolyn K McCourt, Zihan Wei, Kevin Kalinsky, et al.
JCO Precision Oncology|February 20, 2026
Larotrectinib in Patients With Tumors With <i>NTRK</i> Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1ENeal Akhave, Zihe Song, David S Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study GroupTorsten Haferlach, Alexander Kohlmann, Lothar Wieczorek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2025
Concordance between tumor tissue and plasma DNA genotyping in the NCI-MATCH trial (EAY131)Mohamed A Gouda, Filip Janku, Ying Yuan, et al.
Pageof 9